Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MedicalMinute: Early Induction Therapy for IBD
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: April 26, 2021 Expiration: April 25, 2022
Start Activity
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Bristol-Myers Squibb
Bruce E. Sands, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the latest guideline-recommended therapies for initial induction treatment of moderate to severe UC and CD

Information on this Educational Activity

Faculty

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, has disclosed that he has received consulting fees from Abivax, Arena, AstraZeneca, Bacainn, Boehringer Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, Gilead Sciences, GlaxoSmithKline, Index, Inotrem, Ironwood, Janssen, Kallyope, Lilly, Pfizer, Prometheus Biosciences, Prometheus Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, and Viela Bio and funds for research support from Theravance.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Beth-Ann Norton, MS, RN, ANP-BC
Beth-Ann Norton, MS, RN, ANP-BC, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, and Pfizer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 26, 2021, through April 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

MedicalMinute: Early Induction Therapy for IBD
  • CME
  • CE

Loading...
In this concise video, review a synthesis of recommendations from AGA and ACG guidelines on the treatment of moderate to severe UC and CD, and hear expert discussion on the rationale for early induction therapy with a biologic.
Bruce E. Sands, MD, MS
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: April 26, 2021 Expiration: April 25, 2022

Related Content

Expert commentary from Dr. Bruce Sands on STRIDE-II recommendations for treat-to-target goals in IBD, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: May 5, 2021

Downloadable slides covering current guideline recommendations for induction therapy in moderate to severe UC and CD

Bruce E. Sands, MD, MS Released: April 26, 2021

Clinical Care Options (CCO) expert commentary on new data on IBD pathogenesis and management from the 2021 virtual Crohn’s & Colitis Congress

Anita Afzali, MD, MPH, FACG Released: March 5, 2021

Expert commentary from Raymond K. Cross, MD, MS, on management of moderate to severe ulcerative colitis, as reported to Clinical Care Options (CCO)

Raymond K. Cross, MD, MS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 14, 2020 Expired: December 13, 2021
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue